# Prosetta Biosciences Inc

> Prosetta Biosciences is a San Francisco biotech using a proprietary cell-free protein synthesis and assembly (CFPSA) platform to discover small-molecule 'assembly modulators' - drugs that disrupt the multi-protein complexes behind viral infection, cancer, and neurodegeneration. Founded by UCSF physician-scientist Vishwanath Lingappa, the company is advancing candidates against ALS/FTD, Alzheimer's, pan-cancer targets, and antivirals.

- **Founded:** 2003
- **Headquarters:** San Francisco, United States
- **Founders:** Vishwanath R. Lingappa (Founder, CTO & Co-CEO)
- **Team size:** ~24
- **Products:** CFPSA Platform, PAV-615, Oncology Program, Antiviral Program, Alzheimer's Program
- **Notable:** Won ARPA-H Dash to Accelerate Health Outcomes (2023) with 'One Drug for All Cancers' proposal., Raised ~$66M total including $31M Series D from Alger and Takeda., Published in Cell Reports Medicine, Cells, and Clinical Proteomics (2024-2025).

## Products & services

- **CFPSA Platform** — Proprietary cell-free protein synthesis and assembly system used to screen for small molecules that disrupt aberrant multi-protein complexes.
- **PAV-615** — Assembly modulator candidate showing preclinical efficacy in C9orf72-associated ALS/FTD mouse models and human iPSC-derived motor neurons.
- **Oncology Program** — 'One Drug for All Cancers' program advancing assembly modulators with pan-cancer selective cytotoxicity; collaboration with NCI.
- **Antiviral Program** — Lead series of small molecules active against influenza, HIV, HCV, and other viral families.
- **Alzheimer's Program** — Programs targeting oxidized MIF as a relay between external risk factors and tau pathology.

## Achievements

- Won ARPA-H Dash to Accelerate Health Outcomes (2023) with 'One Drug for All Cancers' proposal.
- Raised ~$66M total including $31M Series D from Alger and Takeda.
- Published in Cell Reports Medicine, Cells, and Clinical Proteomics (2024-2025).
- Demonstrated PAV-615 efficacy in C9orf72 ALS/FTD models.
- Identified an ALS assembly modulator signature in peripheral blood mononuclear cells - potential diagnostic.

## Latest updates

- **2025-12** — Two peer-reviewed publications: oxidized MIF as an Alzheimer's drug target (Cell Reports Medicine) and PAV-615 preclinical data in ALS/FTD (Cells).
- **2025-05** — PAV-615 ALS/FTD data presented at Target ALS annual meeting.
- **2025-04** — Clinical Proteomics paper on an ALS assembly modulator signature in peripheral blood mononuclear cells.
- **2025-03** — Webinar on assembly modulation as an emergent cross-therapeutic drug discovery strategy; new pan-cancer cytotoxicity data.
- **2024-12** — Publications on small-molecule protein assembly modulators with pan-cancer efficacy.

## Links

- Website: https://prosetta.com
- LinkedIn: https://www.linkedin.com/company/prosetta

---

Profile page: https://yespress.io/prosetta-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-28